Literature DB >> 20130943

Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.

Masaru Ando1, Eishi Miyazaki, Mari Yamasue, Yukiko Sadamura, Toshihiro Ishii, Ryuichi Takenaka, Takeo Ito, Shin-ichi Nureki, Toshihide Kumamoto.   

Abstract

A 58-year-old male was admitted to our hospital because of periungual nailfold an erythema and erythematous rash on the dorsal joints of his hands and feet, but no muscle weakness. He was thus diagnosed to have amyopathic dermatomyositis. He had moderate hypoxemia and his chest computed tomography scans demonstrated bilateral ground-glass opacities, implicating complication with interstitial pneumonia. Therapy was initiated with pulsed methylprednisolone followed by high-dose corticosteroids, pulsed cyclophosphamide, and cyclosporine. The skin manifestations improved; however, the pulmonary infiltrates and hypoxemia deteriorated during the 2-month period of the treatment. The treatment was switched from cyclosporine to tacrolimus because of an inadequate clinical response to the therapy, and this resulted in the resolution of interstitial pneumonia. This case indicates that tacrolimus administration should be considered for patients with this life-threatening disorder when it is judged to be refractory to cyclosporine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130943     DOI: 10.1007/s10067-009-1358-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  13 in total

1.  Tacrolimus in refractory polymyositis with interstitial lung disease.

Authors:  C V Oddis; F C Sciurba; K A Elmagd; T E Starzl
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

Review 2.  Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis.

Authors:  Richard D Sontheimer; Sachiko Miyagawa
Journal:  J Am Acad Dermatol       Date:  2003-05       Impact factor: 11.527

3.  Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.

Authors:  F S Shihab; T F Andoh; A M Tanner; N A Noble; W A Border; N Franceschini; W M Bennett
Journal:  Kidney Int       Date:  1996-04       Impact factor: 10.612

4.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

5.  Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression.

Authors:  C C Baan; I C van Riemsdijk-van Overbeeke; A H Balk; P M Vantrimpont; W M Mol; C J Knoop; H G Niesters; L P Maat; W Weimar
Journal:  Clin Transplant       Date:  2001-08       Impact factor: 2.863

6.  Interstitial lung diseases associated with amyopathic dermatomyositis.

Authors:  T Suda; T Fujisawa; N Enomoto; Y Nakamura; N Inui; T Naito; D Hashimoto; J Sato; M Toyoshima; H Hashizume; K Chida
Journal:  Eur Respir J       Date:  2006-07-12       Impact factor: 16.671

7.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

8.  Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases.

Authors:  Gen Ideura; Masayuki Hanaoka; Tomonobu Koizumi; Keisaku Fujimoto; Yasuhiro Shimojima; Wataru Ishii; Masayuki Matsuda; Shuichi Ikeda
Journal:  Respir Med       Date:  2007-03-13       Impact factor: 3.415

Review 9.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

10.  Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A.

Authors:  Yasuhiro Shimojima; Wataru Ishii; Takashi Kato; Kenichi Hoshi; Masayuki Matsuda; Takao Hashimoto; Yukio Tanaka; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2003-12       Impact factor: 1.271

View more
  14 in total

Review 1.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Authors:  Roberta Vilela Lopes Koyama; Tiago Kiyoshi Kitabayashi Braga; George Alberto da Silva Dias; Satomi Fujihara; Hellen Thais Fuzii; Gilberto Toshimitsu Yoshikawa
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

2.  Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum.

Authors:  Xiaolei Ma; Zhiyong Chen; Wei Hu; Ziwei Guo; Yan Wang; Masataka Kuwana; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2015-07-07       Impact factor: 2.980

3.  Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.

Authors:  Makiko Yashiro; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Masayuki Miyata; Kiyoshi Migita
Journal:  Fukushima J Med Sci       Date:  2018

4.  HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.

Authors:  Jing Zou; Qiang Guo; Jiachang Chi; Huawei Wu; Chunde Bao
Journal:  Clin Rheumatol       Date:  2015-01-23       Impact factor: 2.980

Review 5.  Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature.

Authors:  Shiro Matsubara; Koichi Kondo; Keizo Sugaya; Kazuhito Miyamoto
Journal:  Clin Rheumatol       Date:  2012-08-12       Impact factor: 2.980

Review 6.  The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review.

Authors:  Yongpeng Ge; Hang Zhou; Jingli Shi; Bin Ye; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2015-09-02       Impact factor: 2.980

7.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

8.  Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.

Authors:  Jing Zou; Jie Chen; Qingran Yan; Qiang Guo; Chunde Bao
Journal:  Clin Rheumatol       Date:  2015-10-12       Impact factor: 2.980

Review 9.  Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.

Authors:  Rekha Vij; Mary E Strek
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

10.  Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease.

Authors:  Leah J Witt; Carley Demchuk; James J Curran; Mary E Strek
Journal:  Pulm Pharmacol Ther       Date:  2016-01-05       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.